cDx – Companion Diagnostics

Diagnostic tests based on the assessment of changes in DNA methylation of disease relevant biomarkers can be used for screening, diagnostic, prognostic and predictive (drug response) purposes, and can be developed as companion diagnostics (cDx).

We offer our technologies and technical /development expertise and capabilities to

Formulate biomarker concepts and strategies
Discover and validate DNA methylation ( epigenetic) biomarkers
Manage diagnostic (GxP-compliant) clinical trials and specimen sourcing
GxP-compliant cDx/IVD development and kit manufacturing
Obtain regulatory approvals
Market and distribute (including partner network) cDx/IVDs.

The company’s partnering approach is flexible and ranges from strategic alliances to fee-for-service arrangements.

For more information please contact business development.

Dr. Nicola Henneberg-Busse
Vice President Business Development
Phone: +49 30 24345-328
bd@epigenomics.com